HN2003000401A - Agonistas morfolinicos de la dopamina - Google Patents

Agonistas morfolinicos de la dopamina

Info

Publication number
HN2003000401A
HN2003000401A HN2003000401A HN2003000401A HN2003000401A HN 2003000401 A HN2003000401 A HN 2003000401A HN 2003000401 A HN2003000401 A HN 2003000401A HN 2003000401 A HN2003000401 A HN 2003000401A HN 2003000401 A HN2003000401 A HN 2003000401A
Authority
HN
Honduras
Prior art keywords
dopamine
agonists
morpholinic
class
agronists
Prior art date
Application number
HN2003000401A
Other languages
English (en)
Inventor
Moria Norfor Allerton Charlotte
Douglas Baxter Andrew
Simon Cook Andrew
Hepworth David
Kwok-Fung Wong Stephen
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0228787A external-priority patent/GB0228787D0/en
Priority claimed from GB0308460A external-priority patent/GB0308460D0/en
Priority claimed from GB0313606A external-priority patent/GB0313606D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of HN2003000401A publication Critical patent/HN2003000401A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UNA CLASE DE AGONISTAS DE LA DOPAMINA, MAS PARTICULARMENTE A UNA CLASE DE AGONISTAS QUE SON SELECTIVOS DEL RECEPTOR D3 POR ENCIMA DEL D2.
HN2003000401A 2002-12-10 2003-12-09 Agonistas morfolinicos de la dopamina HN2003000401A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0228787A GB0228787D0 (en) 2002-12-10 2002-12-10 Morpholine dopamine agonists
GB0308460A GB0308460D0 (en) 2003-04-11 2003-04-11 Morpholine dopamine agonists
GB0313606A GB0313606D0 (en) 2003-06-12 2003-06-12 Morpholine dopamine agonists

Publications (1)

Publication Number Publication Date
HN2003000401A true HN2003000401A (es) 2004-11-23

Family

ID=32512061

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2003000401A HN2003000401A (es) 2002-12-10 2003-12-09 Agonistas morfolinicos de la dopamina

Country Status (37)

Country Link
EP (1) EP1572214B1 (es)
JP (3) JP3889775B2 (es)
KR (1) KR100796102B1 (es)
AP (1) AP2005003325A0 (es)
AR (1) AR042339A1 (es)
AT (1) ATE460938T1 (es)
AU (1) AU2003302878B2 (es)
CA (1) CA2508262C (es)
CO (1) CO5700781A2 (es)
CR (1) CR7869A (es)
CY (1) CY1110130T1 (es)
DE (1) DE60331769D1 (es)
DK (1) DK1572214T3 (es)
EA (1) EA009589B1 (es)
EC (1) ECSP055850A (es)
ES (1) ES2339767T3 (es)
GE (1) GEP20074272B (es)
HK (1) HK1081850A1 (es)
HN (1) HN2003000401A (es)
HR (1) HRP20050523A2 (es)
IS (1) IS7843A (es)
MA (1) MA27605A1 (es)
MX (1) MXPA05006151A (es)
MY (1) MY144338A (es)
NL (1) NL1024983C2 (es)
NO (1) NO330143B1 (es)
NZ (1) NZ540505A (es)
OA (1) OA13014A (es)
PA (1) PA8591601A1 (es)
PE (1) PE20040906A1 (es)
PL (1) PL377480A1 (es)
PT (1) PT1572214E (es)
RS (1) RS51442B (es)
SI (1) SI1572214T1 (es)
TW (1) TW200423944A (es)
UY (1) UY28117A1 (es)
WO (1) WO2004052372A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1753763B1 (en) * 2004-05-26 2008-08-13 Pfizer Limited Indazole and indolone derivatives and their use as pharmaceuticals
CA2567935C (en) * 2004-05-27 2009-10-27 Pfizer Limited Aminopyridine derivatives as selective dopamine d3 agonists
GB0502509D0 (en) 2005-02-07 2005-03-16 Pfizer Ltd Novel salt form of a dopamine agonist
TW200740779A (en) 2005-07-22 2007-11-01 Mitsubishi Pharma Corp Intermediate compound for synthesizing pharmaceutical agent and production method thereof
GB0700786D0 (en) * 2007-01-15 2007-02-21 Pfizer Ltd Morpholine dopamine agonists for the treatment of pain
ES2687095T3 (es) 2010-05-21 2018-10-23 Research Triangle Institute Fenilimorfolinas y análogos de las mismas
ES2546492T3 (es) 2010-05-21 2015-09-24 Research Triangle Institute Derivados de 1-fenilmorfolina como análogos de hidroxibupropion para tratar drogodependencia
WO2015086495A1 (en) 2013-12-11 2015-06-18 F. Hoffmann-La Roche Ag Process for the preparation of chiral 2-aryl morpholines
GB2543296A (en) * 2015-10-13 2017-04-19 Indivior Uk Ltd Dopamine D3 receptor antagonists having a morpholine moiety
EP3725768A1 (en) * 2019-04-17 2020-10-21 Newron Pharmaceuticals S.p.A. Process for the production of substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB851311A (en) * 1958-04-02 1960-10-12 Geigy Ag J R Morpholine compounds and their production
GB9108629D0 (en) * 1991-04-23 1991-06-12 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction

Also Published As

Publication number Publication date
IS7843A (is) 2005-05-12
UY28117A1 (es) 2004-07-30
MA27605A1 (fr) 2005-11-01
CO5700781A2 (es) 2006-11-30
AP2005003325A0 (en) 2005-06-30
EP1572214B1 (en) 2010-03-17
ECSP055850A (es) 2005-09-20
EP1572214A1 (en) 2005-09-14
HK1081850A1 (en) 2006-05-26
CA2508262C (en) 2009-12-01
NO20052557D0 (no) 2005-05-26
PE20040906A1 (es) 2005-01-24
GEP20074272B (en) 2007-12-25
CR7869A (es) 2005-07-08
ES2339767T3 (es) 2010-05-25
PL377480A1 (pl) 2006-02-06
EA200500801A1 (ru) 2005-12-29
RS51442B (en) 2011-04-30
KR100796102B1 (ko) 2008-01-21
DK1572214T3 (da) 2010-06-07
JP2006232857A (ja) 2006-09-07
JP3920908B2 (ja) 2007-05-30
AU2003302878A1 (en) 2004-06-30
CY1110130T1 (el) 2015-01-14
EA009589B1 (ru) 2008-02-28
NO20052557L (no) 2005-09-06
NL1024983C2 (nl) 2005-02-01
RS20050445A (en) 2007-04-10
WO2004052372A1 (en) 2004-06-24
TW200423944A (en) 2004-11-16
HRP20050523A2 (en) 2005-08-31
JP2006511599A (ja) 2006-04-06
NZ540505A (en) 2007-02-23
ATE460938T1 (de) 2010-04-15
KR20050094813A (ko) 2005-09-28
JP4624341B2 (ja) 2011-02-02
OA13014A (en) 2006-11-10
JP3889775B2 (ja) 2007-03-07
DE60331769D1 (de) 2010-04-29
MXPA05006151A (es) 2005-08-26
CA2508262A1 (en) 2004-06-24
JP2007084575A (ja) 2007-04-05
PA8591601A1 (es) 2004-12-16
PT1572214E (pt) 2010-05-06
NL1024983A1 (nl) 2004-06-11
SI1572214T1 (sl) 2010-07-30
MY144338A (en) 2011-08-29
NO330143B1 (no) 2011-02-21
AU2003302878B2 (en) 2009-04-23
AR042339A1 (es) 2005-06-15

Similar Documents

Publication Publication Date Title
CL2021002880S1 (es) Estuche de auriculares. (divisional solicitud 202000595)
PA8576901A1 (es) Moduladores del receptor de glucocorticoides
ECSP066334A (es) Derivados bloqueadores del receptor angiotensina ii
PA8625201A1 (es) Composiciones de peróxido estabilizadas
TW200501455A (en) Light emitting device methods (I)
EA200702643A1 (ru) Антитела, связывающие tweak
HN2001000190A (es) Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento
SG155768A1 (en) Nitride phosphor and production process thereof, and light emitting device
TW200605416A (en) Light emitting device processes
TW200503295A (en) Light emitting devices
TW200503296A (en) Light emitting devices
CR6935A (es) Agentes del receptor b3-adrenergico y usos de los mismos
CL2008003391A1 (es) Compuestos derivados de pirrolidinas, moduladores de la funcion del receptor de androgeno (divisional de la solicitud 970-03).
GT200400071A (es) Compuestos que modulan la actividad de ppar y procedimientos de preparacion
DOP2005000024A (es) 2,3,4,5-tetrahidro-1h-benzo[d]azepinas 6-sustituidas como agonistas del receptor 5-ht2c
TW200505053A (en) Light emitting devices (Ⅰ)
NO20076347L (no) Nye regimer for orale monofasiske befruktningshindrene midler
HN2003000401A (es) Agonistas morfolinicos de la dopamina
PA8654601A1 (es) Agentes citotoxicos que comprenden taxanos nuevos
GT200300258A (es) Activadores de ppar
GT200600156A (es) Compuestos heteroaromaticos acilaminobiciclicos y sus usos
MX2020009286A (es) Antagonistas del receptor de adenosina y usos de los mismos.
CL2011000859A1 (es) Toalla higienica femenina que comprende una parte principal alargada que incluye un area intermedia entre las areas delantera y trasera y un par de aletas que se extienden lateralmente desde el area intermedia y que se componen de un material de color; combinacion de toalla higienica y prenda interior; y toalla higienica.
GT200600187A (es) Moduladores de androgenos
TW200606985A (en) Continuous carbon-nanotube filaments for radiation-emitting devices and related methods